inactiv
sever
acut
respiratori
syndromeassoci
coronaviru
sampl
use
extern
qualiti
assur
studi
within
world
health
organ
sar
refer
verif
network
refer
institut
particip
correctli
detect
viru
sampl
rna
copi
per
millilit
none
neg
sampl
commerci
test
kit
significantli
improv
outcom
ever
acut
respiratori
syndrom
sar
infecti
interstiti
pneumonia
caus
death
consider
portion
patient
first
epidem
sar
began
novemb
southern
china
spread
five
contin
interrupt
juli
caus
death
among
case
two
laboratoryassoci
infect
four
new
isol
case
sinc
occur
sar
caus
novel
coronaviru
sarscov
shed
patient
respiratori
secret
infect
immun
respons
sarscov
appear
latenc
week
infect
concentr
viru
particl
vari
greatli
patient
type
clinic
sampl
thu
achiev
reliabl
virolog
diagnosi
earli
diseas
onset
difficult
highli
sensit
method
viru
detect
revers
transcriptionpolymeras
chain
reaction
rtpcr
requir
confirm
sar
acut
phase
prevent
transmiss
molecular
detect
method
develop
sever
research
laboratori
first
commerci
test
kit
becom
avail
perform
test
howev
evalu
pilot
feasibl
studi
littl
data
exist
rel
perform
differ
laboratori
method
world
health
organ
made
compar
standard
laboratori
test
issu
high
prioriti
sar
research
compar
test
character
sampl
direct
way
identifi
weak
singl
laboratori
certain
method
present
result
first
extern
qualiti
assur
studi
sarscov
molecular
detect
ninetythre
institut
involv
laboratori
diagnost
sar
invit
particip
studi
invite
member
intern
sar
refer
verif
laboratori
network
nation
region
sar
refer
laboratori
studi
announc
extern
qualiti
assur
studi
diagnost
profici
includ
certifi
publish
result
compar
anonym
manner
fiftyeight
laboratori
countri
european
australasian
north
south
american
african
eventu
enrol
studi
four
compani
produc
commerci
diagnost
test
system
also
particip
evalu
separ
fulfil
public
health
duti
viru
materi
obtain
supernat
vero
cell
cultur
collect
one
day
infect
sarscov
strain
frankfurt
supernat
heat
h
irradi
kgi
residu
infect
exclud
vero
cell
cultur
passag
aliquot
inactiv
viru
stock
solut
lyophil
redissolv
viru
rna
quantifi
two
differ
noncommerci
realtim
rtpcr
assay
virion
integr
confirm
morpholog
electron
microscopi
data
shown
test
sampl
studi
gener
dilut
inactiv
viru
stock
solut
human
freshfrozen
plasma
test
neg
hepat
b
viru
hepat
c
viru
sarscov
rtpcr
aliquot
lyophil
ship
ambient
temperatur
particip
laboratori
particip
receiv
code
panel
seven
posit
three
neg
sampl
virusposit
sampl
contain
rna
copi
per
millilit
resuspend
water
particip
ask
analyz
materi
molecular
method
routin
use
suspect
case
human
detail
method
request
sourc
rtpcr
primer
protocol
type
extract
method
use
supplier
type
commerci
kit
use
follow
two
criteria
chosen
minimum
requir
overal
profici
first
laboratori
correctli
detect
four
sampl
contain
copi
viral
rna
per
millilit
concentr
well
detect
limit
publish
commerci
nucleic
acid
amplif
test
nat
sarscov
second
falseposit
result
allow
neg
sampl
indetermin
result
posit
sampl
treat
neg
neg
sampl
treat
posit
sinc
applic
nat
usual
involv
indetermin
endpoint
laboratori
abl
resolv
unclear
result
doubl
test
anoth
amplif
assay
evalu
perform
individu
laboratori
determin
mani
particip
manag
detect
viru
sampl
tabl
concentrationdepend
cumul
posit
rate
per
sampl
correspond
exactli
respons
rate
calcul
probit
regress
analysi
equival
doserespons
model
figur
p
model
could
predict
averag
laboratori
test
result
could
expect
correctli
posit
confid
interv
ci
copi
viru
rna
per
millilit
sampl
present
ci
copi
per
millilit
good
complianc
model
furthermor
confirm
sampl
contain
expect
concentr
rna
upon
recept
particip
rna
degrad
occur
even
sampl
contain
low
amount
viru
appli
profici
criteria
laboratori
pass
minimum
requir
success
particip
failur
three
laboratori
due
lack
sensit
three
due
falseposit
result
one
due
thirteen
success
laboratori
particip
could
also
detect
viru
three
weakli
posit
sampl
copiesml
anoth
miss
one
posit
sampl
ten
laboratori
issu
indetermin
result
one
sampl
whether
common
technic
factor
would
influenc
perform
laboratori
also
assess
subject
cumul
result
low
concentr
sampl
copiesml
analysi
varianc
anova
analysi
overal
posit
rate
sampl
ci
seven
technic
factor
tabl
use
character
test
procedur
laboratori
use
use
commerci
rtpcr
test
kit
made
signific
differ
regard
total
sensit
find
concord
result
four
particip
compani
manufactur
kit
correct
fourteen
particip
use
commerci
test
kit
noncommerci
test
whether
laboratori
develop
primer
adapt
research
make
differ
find
might
due
avail
wellevalu
primer
internet
resourc
outbreak
fortytwo
particip
use
least
one
procedur
list
site
final
assess
whether
laboratori
belong
intern
sar
refer
verif
network
profici
sar
molecular
detect
other
three
sampl
contain
lab
particip
studi
differ
signific
p
valu
ttest
result
first
extern
qualiti
assur
studi
sarscov
molecular
detect
assur
compar
earlier
studi
molecular
test
filovirus
lassa
viru
orthopoxvirus
use
similar
profici
criteria
almost
doubl
portion
particip
laboratori
complet
studi
success
vs
hand
studi
examin
paramount
issu
like
sensit
control
contamin
valid
aspect
like
crossreact
primer
control
pcr
inhibit
respons
diagnost
laboratori
commerci
test
clearli
prefer
way
achiev
good
diagnost
perform
possibl
sarscov
pathogen
rel
laboratori
experi
howev
develop
approv
commerci
test
lengthi
process
high
cost
limit
applic
approach
adopt
effici
provid
good
diagnost
tool
immedi
respons
infecti
diseas
outbreak
strategi
dissemin
essenti
inform
public
internet
resourc
public
proven
success
laboratori
willingli
share
protocol
posit
control
materi
institut
enabl
qualifi
diagnost
within
week
primari
descript
new
viru
benefit
proven
good
overal
result
studi
intern
strain
collect
complement
noninfecti
refer
materi
rare
pathogen
materi
avail
highli
preval
agent
like
herp
virus
hepat
virus
sarscov
refer
materi
creat
studi
first
time
sampl
describ
obtain
nonprofit
charg
sar
refer
verif
laboratori
network
